Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 10/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31758278 | 0.90 | ALB (0.62) | ALBKMT2AMDM2CA9TLR2 | |
| SCHEMBL20530026 | 0.90 | ALB (0.53) | ALBKMT2AMDM2CA9TLR2 | |
| SCHEMBL24193273 | 0.85 | MDM2 (0.55) | ALBKMT2AMDM2TLR2 | |
| SCHEMBL31298671 | 0.84 | ALB (0.48) | ALBKMT2AMDM2CA9TLR2 | |
| SCHEMBL31298693 | 0.83 | ALB (0.48) | ALBCA9TLR2 | |
| SCHEMBL29423590 | 0.83 | KMT2A (0.64) | KMT2AMDM2TLR2 | |
| SCHEMBL119709 | 0.83 | KMT2A (0.64) | KMT2AMDM2TLR2 | |
| SCHEMBL18148920 | 0.83 | KMT2A (0.64) | KMT2AMDM2TLR2 | |
| SCHEMBL29401604 | 0.83 | KMT2A (0.64) | KMT2AMDM2TLR2 | |
| SCHEMBL119708 | 0.83 | KMT2A (0.64) | KMT2AMDM2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024112612-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-05-30 | — | — | WO | disclosed |